Skip to main content

Peer Review reports

From: Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer

Original Submission
13 Jan 2021 Submitted Original manuscript
24 Feb 2021 Reviewed Reviewer Report - Eun-Kee Song
24 Mar 2021 Reviewed Reviewer Report
10 Apr 2021 Reviewed Reviewer Report
1 May 2021 Author responded Author comments - Luchuan Chen
Resubmission - Version 2
1 May 2021 Submitted Manuscript version 2
14 May 2021 Reviewed Reviewer Report
18 May 2021 Reviewed Reviewer Report - Eun-Kee Song
30 May 2021 Author responded Author comments - Luchuan Chen
Resubmission - Version 3
30 May 2021 Submitted Manuscript version 3
2 Jun 2021 Author responded Author comments - Luchuan Chen
Resubmission - Version 4
2 Jun 2021 Submitted Manuscript version 4
2 Jun 2021 Author responded Author comments - Luchuan Chen
Resubmission - Version 5
2 Jun 2021 Submitted Manuscript version 5
3 Jun 2021 Author responded Author comments - Luchuan Chen
Resubmission - Version 6
3 Jun 2021 Submitted Manuscript version 6
6 Jun 2021 Reviewed Reviewer Report - Eun-Kee Song
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
7 Jun 2021 Editorially accepted
15 Jun 2021 Article published 10.1186/s12885-021-08459-3

You can find further information about peer review here.

Back to article page